More than 140 Australians suffering from type 1 or 2 diabetes will participate in the study, run by the Baker Heart and Diabetes Institute, which will begin in September.

A drug developed by researchers at Monash University that blocks a pathway through which NOX enzymes cause damage to the kidneys will be tested in the trial.

Monash's Mark Cooper said that blocking the pathway in mice had prevented kidney damage and the drug, the rights to which are owned by Swiss pharmaceutical company Genkyotex, has shown promise in repairing eye and heart damage related to diabetes.

"In the diabetic kidney three things happen: it scars, it gets inflamed, and it leaks the protein albumin," Cooper told Australian media on Wednesday.

"We were able to show this drug stopped the protein leaking, stopped the inflammation, and stopped the scarring. It's the scarring, particularly, that causes kidney failure."

The 142 study participants will have their urine tested for albumin and then be administered the NOX-inhibitor or a placebo for 12 months.

Diabetes affects 250,000 Australians and Cooper said kidney disease is one of the most common causes of death associated with the disease.

"If we can slow down kidney disease, and also reduce heart and eye disease in the diabetes population, it will dramatically improve lifespan and quality of life," he said.

"These people (sufferers of both type 1 and 2 diabetes) can avoid dialysis, have fewer heart attacks, and suffer less blindness."

Chinese premier wants innovation to play bigger role in economic transformation

Video: preview of 2017 World Robot Conference

Wildfire re-erupts in central Georgia

Rescuers race against time on Italy's Ischia Island, after quake kills two

At least 2 died, 8 injured in knife attack in Turku, Finland

13 killed, over 100 others injured in Barcelona attack: official

Over 400 killed in mudslides in Sierra Leone

Qiandaohu Lake in China's Zhejiang under stricter protection

LOS ANGELES, Aug. 21 (Xinhua) -- If cigarettes prices increase one U.S. dollar more, 20 percent U.S. smokers would be more likely to quit, according a new research report.

Based on results from the new study, published in Epidemiology, raising cigarette prices appears to be a better strategy for encouraging smoking cessation across all ages.

Smoking cessation remains the largest measure against preventable cause of death and disease in the world. People who stop smoking greatly reduce their risk for disease and early death.

According to U.S. Centers for Disease Control and Prevention (CDC), among all current U.S. adult cigarette smokers, nearly 7 out of every 10 reported in 2015 that they wanted to quit completely.

"Our finding that increases in cigarette prices were associated with quitting smoking in the older population suggests that cigarette taxes may be a particularly effective lever for behavior change," Stephanie Mayne, the lead author of the study, said in a statement.

The research team used 10 years of neighborhood-level price data to see how it affected nearby smokers' smoking habits, with particular attention given to those who appeared to be older.

The results are quite surprising: when cigarettes pack prices increased by only one U.S. dollar, current smokers were 20 percent more likely to quit smoking. Heavy smokers, defined as smoking more than half a pack a day, showed a 35 percent reduction in the average number of cigarettes they smoked per day. And overall the price rise resulted in a three percent reduction in smoking risk.

"Some research suggests younger adults may be more price-sensitive than older adults," Mayne added.

Although the health benefits are greater for people who stop at earlier ages, there are benefits at any age, CDC pointed out.

Researchers believe that more consistent tax policy across the United States might help encourage more older adults to quit smoking.

"Given our findings, if an additional one dollar was added to the U.S. tobacco tax, it could amount to upwards of one million fewer smokers," Amy Auchincloss, the senior author on the study and associate professor in the Dornsife School of Public Health, said.

Mobile fingerprinting Dallas offers black ink bases fingerprinting whenever a client needs it. This service is certified by the Texas department of public safety and uses the standard FBI fingerprint cards. The staff performing the task are fully trained and have years of experience therefore issues of mix-ups and mistakes is out of the question.

As one wishes, the service can be availed at their offices or have the staff travel to wherever the client is. They are usually available all through the week even in emergencies. And the good thing about it is that it takes only ten minutes to complete for one person. Other than the decades old use of fingerprints in criminal courts, there are other emerging uses.